• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用SCORE2和SCORE2-OP评估心血管风险状况:运用新的欧洲预测模型比较葡萄牙、西班牙、意大利和法国

Cardiovascular risk profile with SCORE2 and SCORE2-OP: comparing Portugal, Spain, Italy, and France using the new European predictive models.

作者信息

Fontainhas Mariana, Gavina Cristina, Miranda Joana, Pereira-Silva Raquel, Guichard João, Seixas Daniela, Araújo Francisco

机构信息

Tonic App, Porto, Portugal.

Unidade Local de Saúde de Matosinhos, Senhora da Hora, Portugal.

出版信息

Front Cardiovasc Med. 2024 Dec 18;11:1509240. doi: 10.3389/fcvm.2024.1509240. eCollection 2024.

DOI:10.3389/fcvm.2024.1509240
PMID:39744208
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11688618/
Abstract

INTRODUCTION

This study aims to characterize the cardiovascular risk profile in countries with low-to-moderate cardiovascular mortality risk (Italy, Portugal, France, and Spain) using the SCORE2 and SCORE2-OP models. It also examines regional variations and the involvement of healthcare professionals in performing risk assessments.

METHODS

A retrospective observational study was conducted using data from 24,434 cardiovascular risk assessments performed between December 2022 and July 2023 through a digital application used by physicians. The assessments used the SCORE2 model for individuals aged 40-69 and the SCORE2-OP model for those aged 70 and older. Risk stratification into "low-to-moderate," "high," and "very high" categories was analyzed based on individual risk factors such as age, smoking habits, systolic blood pressure, and cholesterol levels.

RESULTS

Approximately 50%-60% of individuals in these countries were classified as having "high" or "very high" cardiovascular risk. The highest proportions were observed in Portugal (62.44%) and Italy (64.05%), while lower proportions were found in Spain (46.65%) and France (52.74%). Regional analysis identified areas with the highest cardiovascular risk, such as Portalegre in Portugal and Apulia in Italy. Key risk factors included older age, smoking, high systolic blood pressure, and high non-HDL cholesterol. General practitioners were the primary healthcare professionals conducting these assessments.

DISCUSSION

The study highlights a significant proportion of individuals with "high" or "very high" cardiovascular risk in countries with low-to-moderate mortality risk. These findings underscore the need for targeted cardiovascular disease prevention strategies and the crucial role of general practitioners in managing cardiovascular risk.

摘要

引言

本研究旨在使用SCORE2和SCORE2-OP模型,对心血管疾病死亡率风险低至中等的国家(意大利、葡萄牙、法国和西班牙)的心血管风险状况进行特征描述。研究还考察了地区差异以及医疗保健专业人员在进行风险评估中的参与情况。

方法

进行了一项回顾性观察研究,使用的数据来自2022年12月至2023年7月期间通过医生使用的数字应用程序进行的24434次心血管风险评估。对于40-69岁的个体,评估使用SCORE2模型;对于70岁及以上的个体,评估使用SCORE2-OP模型。根据年龄、吸烟习惯、收缩压和胆固醇水平等个体风险因素,分析了分为“低至中等”、“高”和“非常高”类别的风险分层。

结果

这些国家中约50%-60%的个体被归类为具有“高”或“非常高”的心血管风险。葡萄牙(62.44%)和意大利(64.05%)的比例最高,而西班牙(46.65%)和法国(52.74%)的比例较低。区域分析确定了心血管风险最高的地区,如葡萄牙的波塔莱格雷和意大利的普利亚。关键风险因素包括年龄较大、吸烟、收缩压高和非高密度脂蛋白胆固醇高。全科医生是进行这些评估的主要医疗保健专业人员。

讨论

该研究强调,在心血管疾病死亡率风险低至中等的国家中,有很大比例的个体具有“高”或“非常高”的心血管风险。这些发现强调了针对性心血管疾病预防策略的必要性,以及全科医生在管理心血管风险方面的关键作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be81/11688618/834aeb083163/fcvm-11-1509240-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be81/11688618/9bdc0e6193a3/fcvm-11-1509240-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be81/11688618/820202027f99/fcvm-11-1509240-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be81/11688618/2a4811346810/fcvm-11-1509240-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be81/11688618/d79c286cc06b/fcvm-11-1509240-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be81/11688618/834aeb083163/fcvm-11-1509240-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be81/11688618/9bdc0e6193a3/fcvm-11-1509240-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be81/11688618/820202027f99/fcvm-11-1509240-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be81/11688618/2a4811346810/fcvm-11-1509240-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be81/11688618/d79c286cc06b/fcvm-11-1509240-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be81/11688618/834aeb083163/fcvm-11-1509240-g005.jpg

相似文献

1
Cardiovascular risk profile with SCORE2 and SCORE2-OP: comparing Portugal, Spain, Italy, and France using the new European predictive models.使用SCORE2和SCORE2-OP评估心血管风险状况:运用新的欧洲预测模型比较葡萄牙、西班牙、意大利和法国
Front Cardiovasc Med. 2024 Dec 18;11:1509240. doi: 10.3389/fcvm.2024.1509240. eCollection 2024.
2
Cardiovascular Risk Assessment and Control in Outpatients Evaluated by 24-hour Ambulatory Blood Pressure and Different LDL-C Equations.门诊患者 24 小时动态血压和不同 LDL-C 方程评估的心血管风险评估和控制。
High Blood Press Cardiovasc Prev. 2023 Nov;30(6):551-560. doi: 10.1007/s40292-023-00605-1. Epub 2023 Oct 30.
3
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.新的系统性冠状动脉风险评估(SCORE2 和 SCORE2-OP)评估了接受尼罗替尼或帕纳替尼治疗的慢性髓性白血病患者发生动脉闭塞性事件的风险。
Ann Hematol. 2024 Feb;103(2):427-436. doi: 10.1007/s00277-023-05556-0. Epub 2023 Nov 28.
4
[Cardiovascular risk assessment among patients with hypertension based on SCORE2 and SCORE-OP algorithms in black Africans].基于SCORE2和SCORE-OP算法对非洲裔高血压患者进行心血管风险评估
Ann Cardiol Angeiol (Paris). 2023 Jun;72(3):101602. doi: 10.1016/j.ancard.2023.101602. Epub 2023 May 13.
5
Cardiovascular risk assessment in Portugal's primary health care system: SCORE vs. SCORE2.葡萄牙初级卫生保健系统中心血管风险评估:SCORE 与 SCORE2。
Rev Port Cardiol. 2024 Aug;43(8):449-455. doi: 10.1016/j.repc.2023.10.012. Epub 2024 Feb 21.
6
Systematic Coronary Risk Evaluation 2 for Older Persons: 10 years risk validation, clinical utility, and potential improvement.老年人系统性冠状动脉风险评估2:10年风险验证、临床效用及潜在改进
Eur J Prev Cardiol. 2025 May 12;32(7):527-536. doi: 10.1093/eurjpc/zwae383.
7
Cardiovascular Risk Scores and Migraine Status.心血管风险评分与偏头痛状况。
JAMA Netw Open. 2024 Oct 1;7(10):e2440577. doi: 10.1001/jamanetworkopen.2024.40577.
8
Validation of the SCORE2 risk prediction algorithm in a Portuguese population: A new model to estimate 10-year cardiovascular disease incidence in Europe.验证 SCORE2 风险预测算法在葡萄牙人群中的应用:一种用于估计欧洲人群 10 年心血管疾病发生率的新模型。
Rev Port Cardiol. 2024 Aug;43(8):437-444. doi: 10.1016/j.repc.2023.10.011. Epub 2024 Feb 21.
9
Advancing cardiovascular risk assessment: Real-time SCORES2 calculation through CDSS in primary care patients.
Clin Biochem. 2025 Jun;137:110922. doi: 10.1016/j.clinbiochem.2025.110922. Epub 2025 Apr 17.
10
Cardiovascular risk assessment using SCORE2 in a population with hypertension - The reality at a primary health care unit.应用 SCORE2 对高血压人群进行心血管风险评估 - 基层医疗单位的实际情况。
Rev Port Cardiol. 2024 Nov;43(11):601-610. doi: 10.1016/j.repc.2024.03.007. Epub 2024 Jul 14.

本文引用的文献

1
Differences of cardiovascular risk assessment in clinical practice using SCORE and SCORE2.应用 SCORE 和 SCORE2 评估临床实践中心血管风险的差异。
Open Heart. 2022 Nov;9(2). doi: 10.1136/openhrt-2022-002087.
2
Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data.基于人群的队列研究LATINO中的心血管风险概况与血脂管理:20年真实世界数据
J Clin Med. 2022 Nov 18;11(22):6825. doi: 10.3390/jcm11226825.
3
Performance of SCORE2 and SCORE2-OP risk algorithms in a Cypriot cohort.
塞浦路斯队列中 SCORE2 和 SCORE2-OP 风险算法的性能。
Int Angiol. 2022 Dec;41(6):492-499. doi: 10.23736/S0392-9590.22.04958-6. Epub 2022 Oct 26.
4
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.2021年欧洲心脏病学会临床实践中心血管疾病预防指南。
Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484.
5
SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions.SCORE2-OP 风险预测算法:估计四个地理风险地区老年人的新发心血管事件风险。
Eur Heart J. 2021 Jul 1;42(25):2455-2467. doi: 10.1093/eurheartj/ehab312.
6
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe.SCORE2 风险预测算法:用于评估欧洲人群 10 年心血管疾病风险的新模型。
Eur Heart J. 2021 Jul 1;42(25):2439-2454. doi: 10.1093/eurheartj/ehab309.
7
Associations of healthy lifestyle and socioeconomic status with mortality and incident cardiovascular disease: two prospective cohort studies.健康生活方式和社会经济地位与死亡率和心血管疾病发病的关联:两项前瞻性队列研究。
BMJ. 2021 Apr 14;373:n604. doi: 10.1136/bmj.n604.
8
A Comparison of Four Cardiovascular Risk Assessment Instruments in Saudi Patients.沙特患者中四种心血管风险评估工具的比较
Cureus. 2020 Feb 24;12(2):e7093. doi: 10.7759/cureus.7093.
9
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.2019年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南:通过血脂修饰降低心血管风险
Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.
10
2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).2016年欧洲临床实践心血管疾病预防指南:欧洲心脏病学会和其他学会关于临床实践心血管疾病预防的第六联合工作组(由10个学会的代表和特邀专家组成)由欧洲心血管预防与康复协会(EACPR)特别贡献制定。
Eur Heart J. 2016 Aug 1;37(29):2315-2381. doi: 10.1093/eurheartj/ehw106. Epub 2016 May 23.